NOVA MSC BERHAD
01 December 2025
1. INTRODUCTION
The Board of Directors of the Company (“the Board”) wishes to announce that Dex-lab Pte Ltd (“Dex-lab”), a subsidiary of the Company, has appointed Evolve Capital Advisory Private Limited as the sponsor for Dex-lab’s proposed listing on the Catalist Board of the Singapore Exchange Securities Trading Limited (“SGX”).
2. DETAILS OF THE PROPOSED LISTING
The proposed listing forms part of Dex-lab’s strategy to expand its humanoid robotics and eldercare technology business across Singapore, Hong Kong, Australia and other markets in the Asia-Pacific region. The appointment of a Sponsor is the first formal step in the SGX Catalist listing process.
The proposed listing remains subject to:
(a) completion of financial, legal and operational due diligence;
(b) compliance with SGX Catalist listing requirements;
(c) approvals from SGX and other relevant regulatory authorities;
(d) approval from the shareholders of NOVAMSC, where required; and
(e) favourable market conditions.
Further details of the proposed listing structure, utilisation of proceeds, and financial effects on the Group will be announced once finalised.
3. RATIONALE
The proposed listing is expected to strengthen Dex-lab’s capital base, enhance its visibility within the robotics and healthcare technology sectors, and support expansion into new markets. It will also enable Dex-lab to accelerate R&D investment, scale manufacturing capability and strengthen partnerships with healthcare providers.
4. FINANCIAL IMPACT
As the proposed listing exercise is at a preliminary stage, the financial impact on NOVAMSC cannot be determined at this juncture. A further announcement will be made once the structure and terms are finalised.
5. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTERESTS
None of the Directors and major shareholders of NOVAMSC, or persons connected to them, have any interest in the proposed listing, save for their respective interests through Dex-lab and NOVAMSC.
6. STATEMENT BY THE BOARD
The Board is of the view that the proposed listing is in the best interest of the Group, taking into consideration Dex-lab’s growth trajectory, market opportunities, and capital requirements.
7. FURTHER ANNOUNCEMENTS
The Company will make further announcements to Bursa Malaysia Securities Berhad as required.
About Evolve Capital Advisory Private Limited
Evolve Capital Advisory Private Limited is a Singapore-based, MAS-licensed corporate finance advisory firm and accredited SGX Issue Manager and Catalist Full Sponsor, with a strong track record in listings, equity fund-raisings and corporate transactions for growth companies across Southeast Asia.
Comments are closed.